Imunon, Inc. Files 8-K for Financial Results
Ticker: IMNN · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0000749647
Sentiment: neutral
Topics: financial-results, 8-k
Related Tickers: IMUN
TL;DR
IMUN dropped an 8-K with financial results on 3/31/26 - check the exhibits for deets.
AI Summary
Imunon, Inc. filed an 8-K on March 31, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with specific details expected to be found within the attached documents.
Why It Matters
This 8-K filing provides investors with crucial updates on Imunon, Inc.'s financial performance and operational status as of March 31, 2026.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial results and does not inherently indicate new risks.
Key Players & Entities
- Imunon, Inc. (company) — Filer of the 8-K
- 0000749647 (company) — CIK number for Imunon, Inc.
- 2026-03-31 (date) — Filing date and period of report
FAQ
What specific financial results are reported in this 8-K?
The filing indicates Item 2.02: Results of Operations and Financial Condition, with specific details to be found in the attached documents, including EX-99.1.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 31, 2026, at 08:05:35.
What are the business and mailing addresses for Imunon, Inc.?
Both the business and mailing addresses are listed as 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648.
What is Imunon, Inc.'s SIC code and industry classification?
The SIC code is 2834 for Pharmaceutical Preparations, with an Office classification of 03 Life Sciences.
What types of documents are included in this filing?
The filing includes the 8-K form, an exhibit EX-99.1, a graphic file, and various XBRL files for interactive data.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2026-03-31 08:05:35
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 86KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-26-013816.txt ( ) — 307KB
- imnn-20260331.xsd (EX-101.SCH) — 3KB
- imnn-20260331_lab.xml (EX-101.LAB) — 33KB
- imnn-20260331_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
forward-looking statements
forward-looking statements. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 31, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON INC. Dated: March 31, 2026 By: /s/ Jeffrey Church Jeffrey Church Chief Financial Officer